Use of vitamin C and E in the treatment of Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 452-457

  Arlt, Sönke ^a   Müller Thomsen, Tomas ^a   Beisiegel, Ulrike ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Alzheimer's disease; Antioxidants; Lipid peroxidation; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; SELEGILINE;

ALZHEIMER DISEASE; DRUG EFFICACY; HUMAN; LIPID PEROXIDATION; LIPOPHILICITY; MICROGLIA; MOLECULAR INTERACTION; OXIDATIVE STRESS; PHASE TRANSITION; REVIEW; RISK BENEFIT ANALYSIS; VITAMIN SUPPLEMENTATION;

EID: 0036660259     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10107     Document Type: Review

References (45)

1. Arlt S, Finckh B, Beisiegel U, Kontush A. 2000. Time-course of oxidation of lipids in human cerebrospinal fluid in vitro. Free Radic Res 32:103-114.
2. Arlt S, Beisiegel U, Kontush A. 2002. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr Opin Lipidol 13:289-294.
3. Arrol S, Mackness MI, Durrington PN. 2000. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis 150:129-134.
4. Bassett CN, Neely MD, Sidell KB, Markesbery WB, Swift LL, Montine TJ. 1999. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 34:1273-1280.
5. Behl C, Davis J, Cole GM, Schubert D. 1992. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 186:944-950.
6. Bendich A, Langseth L. 1995. The health effects of vitamin C supplementation: a review. J Am Coll Nutr 14:124-136.
7. Bush AI. 2000. Metals and neuroscience. Curr Opin Chem Biol 4:184-191.
8. Clement M, Bourre JM. 1997. Graded dietary levels of RRR-gamma-tocopherol induce a marked increase in the concentrations of alpha- and gamma-tocopherol in nervous tissues, heart, liver, and muscle of vitamin-E-deficient rats. Biochim Biophys Acta 1334:173-181.
9. Fahn S. 1992. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 (suppl):S128-S132.
10. Frei B, England L, Ames BN. 1989. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86:6377-6381.
11. Grundman M. 2000. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71:630S-636S.
12. Kalaria RN. 1999. Microglia and Alzheimer's disease. Curr Opin Hematol 6:15-24.
13. Kolsch H, Ludwig M, Lutjohann D, Rao ML. 2001. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm 108:475-488.
14. Kontush A, Beisiegel U. 1999. Measurement of oxidizability of blood plasma. Methods Enzymol 49:29935-29949.
15. Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller-Thomsen T, Beisiegel U. 2001. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31:345-354.
16. Lonnrot K, Metsa-Ketela T, Molnar G, Ahonen JP, Latvala M, Peltola J, Pietila T, Alho H. 1996. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Free Radic Biol Med 21:211-217.
17. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. 1995. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594-1601.
18. Lovell MA, Xie C, Markesbery WR. 2001. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-194.
19. Markesbery WR. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
20. Markesbery WR, Lovell MA. 1998. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36.
21. McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S, Passmore AP. 2001. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94:485-490.
22. Meydani M, Macauley JB, Blumberg JB. 1988. Effect of dietary vitamin E and selenium on susceptibility of brain regions to lipid peroxidation. Lipids 23:405-409.
23. Meydani SN, Meydani M, Blumberg JB, Leka LS, Pedrosa M, Diamond R, Schaefer EJ. 1998. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 68:311-318.
24. Montine KS, Olson SJ, Amarnath V, Whetsell WO, Jr., Graham DG, Montine TJ. 1997. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 150:437-443.
25. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. 1999. Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562-565.
26. Neely MD, Sidell KR, Graham DG, Montine TJ. 1999. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 72:2323-2333.
27. Neuzil J, Weber C, Kontush A. 2001. The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherosclerosis 157:257-283.
28. Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disibility in early Parldnson's disease. N Engl J Med 328:176-183.
29. Picklo MJ, Montine TJ. 2001. Acrolein inhibits respiration in isolated brain mitochondria. Biochim Biophys Acta 1535:145-152.
30. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. 1998. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12:1777-1783.
31. Reiber H, Ruff M, Uhr M. 1993. Ascorbate concentration in human cerebrospinal fluid (CSF) and serum. Intrathecal accumulation and CSF flow rate. Clin Chim Acta 217:163-173.
32. Rice ME. 2000. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci 23:209-216.
33. Rifici VA, Khachadurian AK. 1993. Dietary supplementation with vitamins C and E inhibits in vitro oxidation of lipoproteins. J Am Coll Nutr 12:631-637.
34. Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G, Smith MA. 2000. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? Mech Aging Dev 116:169-179.
35. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Eugl J Med 336:1216-1222.
36. Sayre LM, Smith MA, Perry G. 2001. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721-738.
37. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092-2097.
38. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U. 2000. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 28:351-360.
39. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. 1991. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88:10540-10543.
40. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. 1996. Oxidative damage in Alzheimer's. Nature 382:120-121.
41. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. 2000. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2:413-420.
42. Spector R, Lorenzo AV. 1973. Ascorbic acid homeostasis in the central nervous system. Am J Physiol 225:751-763.
43. Steinberg D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966.
44. Stocker R. 1994. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 5:422-433.
45. Vatassery GT. 1998. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 53 (suppl 1):S25-S27.